Johnson & Johnson to Attend Goldman Sachs Global Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Should l Buy JNJ?
Source: Newsfilter
- Conference Participation: Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, with management engaging in a Fireside Chat at 10:00 a.m. Eastern Time to showcase the company's latest developments and strategic direction in healthcare.
- Investor Engagement: The Fireside Chat will be live-streamed on Johnson & Johnson's official website, allowing investors and other interested parties to access real-time information, thereby enhancing interaction and transparency with stakeholders.
- Replay Availability: An audio replay of the webcast will be available approximately 48 hours after the live event, ensuring that investors who cannot attend in real-time can still access the content, further improving information accessibility and corporate transparency.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, media-relations@its.jnj.com and investor-relations@its.jnj.com, respectively, facilitating further inquiries and support, thereby strengthening communication with external stakeholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 221.320
Low
190.00
Averages
218.50
High
240.00
Current: 221.320
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson to Attend Goldman Sachs Global Healthcare Conference
- Conference Participation: Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, with management engaging in a Fireside Chat at 10:00 a.m. Eastern Time to showcase the company's latest developments and strategic direction in healthcare.
- Investor Engagement: The Fireside Chat will be live-streamed on Johnson & Johnson's official website, allowing investors and other interested parties to access real-time information, thereby enhancing interaction and transparency with stakeholders.
- Replay Availability: An audio replay of the webcast will be available approximately 48 hours after the live event, ensuring that investors who cannot attend in real-time can still access the content, further improving information accessibility and corporate transparency.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, media-relations@its.jnj.com and investor-relations@its.jnj.com, respectively, facilitating further inquiries and support, thereby strengthening communication with external stakeholders.
See More
Navigating Growth vs. Income Stocks Amid Market Volatility
- Market Volatility Analysis: Equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stock Potential: Eli Lilly exemplifies growth potential, with a 56% year-over-year revenue increase to $19.8 billion in Q1, showcasing its dominance in the weight-loss drug market and the likelihood of launching more drugs in the next five years, appealing to high-risk investors.
- Income Stock Stability: Johnson & Johnson, a 'Dividend King' with 64 consecutive years of dividend increases, offers a 2.35% dividend yield, making it suitable for income-seeking investors, particularly those nearing retirement who prefer stability.
- Investment Strategy Considerations: In the current market environment, investors must weigh their personal investment goals and risk tolerance when choosing between growth and income stocks to achieve optimal returns.
See More
Investors' Dilemma: Growth vs. Dividend Stocks
- Market Volatility Impact: The equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stocks' Risk and Reward: Growth stocks tend to be more volatile and may suffer greater losses during economic downturns; however, for long-term investors, market crashes can present opportunities to buy at lower prices, potentially leading to higher returns.
- Stability of Dividend Stocks: Dividend stocks like Johnson & Johnson provide lower volatility and long-term returns for investors nearing retirement, with a remarkable record of 64 consecutive years of dividend increases, showcasing their reliability.
- Eli Lilly's Growth Potential: Eli Lilly reported a 56% year-over-year revenue increase in Q1, reaching $19.8 billion, with earnings per share at $8.26, highlighting its dominance in the weight-loss drug market and promising future growth prospects.
See More
In-Depth Analysis of Strong Holdings
- Holding Analysis: In the latest 13F filings, 64 hedge funds held Johnson & Johnson (JNJ), indicating widespread interest in the stock, although these reports only reflect long positions.
- Position Changes: As of March 31, 2026, 19 funds increased their JNJ holdings while 34 decreased theirs, showcasing a divergence in market sentiment towards the stock.
- Aggregate Growth: The total holdings of hedge funds in JNJ rose from 349,344,815 shares on December 31, 2025, to 603,016,125 shares, representing an increase of approximately 72.61%, reflecting strong confidence in the company.
- Key Fund Movements: Guardian Capital LLC exited its JNJ position in the latest 13F filings, indicating varying investment strategies and risk assessments within the market.
See More
Goldman Sachs Retirement Survey Reveals Optimism Gap
- Optimism Gap Phenomenon: The Goldman Sachs Retirement Survey reveals that while 68% of workers are confident about meeting retirement goals, 58% fear outliving their savings, highlighting a structural cost pressure that has reduced the capacity for retirement savings due to rising housing, childcare, and healthcare costs.
- Increased Spending Pressures: Since 2000, housing costs have risen from 21% to 36% of income, childcare from 10% to 25%, and healthcare from 12% to 33%, leading to 67% of respondents feeling overwhelmed by monthly expenses and 64% experiencing financial hardship, which directly impacts their retirement planning.
- Income Strategy Enhancement: The survey indicates that a blended income strategy combining protected lifetime income with investment withdrawals can increase retirement income by 23%, providing stability for essential expenses while addressing long-term growth needs, thereby alleviating financial pressure during retirement.
- Behavioral Factors Impact: Goldman’s research shows that retirees with personalized plans have a savings-to-income ratio of 5.92x compared to 4.68x for those without, underscoring the importance of combining structure and behavior in achieving better retirement outcomes and emphasizing the need for consistent saving and planning.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Johnson & Johnson to Attend Goldman Sachs Global Healthcare Conference
- Conference Participation: Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, with management engaging in a Fireside Chat at 10:00 a.m. Eastern Time to showcase the company's latest developments and strategic direction in healthcare.
- Investor Engagement: The Fireside Chat will be live-streamed on Johnson & Johnson's official website, allowing investors and other interested parties to access real-time information, thereby enhancing interaction and transparency with stakeholders.
- Replay Availability: An audio replay of the webcast will be available approximately 48 hours after the live event, ensuring that investors who cannot attend in real-time can still access the content, further improving information accessibility and corporate transparency.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, media-relations@its.jnj.com and investor-relations@its.jnj.com, respectively, facilitating further inquiries and support, thereby strengthening communication with external stakeholders.
See More
Navigating Growth vs. Income Stocks Amid Market Volatility
- Market Volatility Analysis: Equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stock Potential: Eli Lilly exemplifies growth potential, with a 56% year-over-year revenue increase to $19.8 billion in Q1, showcasing its dominance in the weight-loss drug market and the likelihood of launching more drugs in the next five years, appealing to high-risk investors.
- Income Stock Stability: Johnson & Johnson, a 'Dividend King' with 64 consecutive years of dividend increases, offers a 2.35% dividend yield, making it suitable for income-seeking investors, particularly those nearing retirement who prefer stability.
- Investment Strategy Considerations: In the current market environment, investors must weigh their personal investment goals and risk tolerance when choosing between growth and income stocks to achieve optimal returns.
See More
Investors' Dilemma: Growth vs. Dividend Stocks
- Market Volatility Impact: The equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stocks' Risk and Reward: Growth stocks tend to be more volatile and may suffer greater losses during economic downturns; however, for long-term investors, market crashes can present opportunities to buy at lower prices, potentially leading to higher returns.
- Stability of Dividend Stocks: Dividend stocks like Johnson & Johnson provide lower volatility and long-term returns for investors nearing retirement, with a remarkable record of 64 consecutive years of dividend increases, showcasing their reliability.
- Eli Lilly's Growth Potential: Eli Lilly reported a 56% year-over-year revenue increase in Q1, reaching $19.8 billion, with earnings per share at $8.26, highlighting its dominance in the weight-loss drug market and promising future growth prospects.
See More
In-Depth Analysis of Strong Holdings
- Holding Analysis: In the latest 13F filings, 64 hedge funds held Johnson & Johnson (JNJ), indicating widespread interest in the stock, although these reports only reflect long positions.
- Position Changes: As of March 31, 2026, 19 funds increased their JNJ holdings while 34 decreased theirs, showcasing a divergence in market sentiment towards the stock.
- Aggregate Growth: The total holdings of hedge funds in JNJ rose from 349,344,815 shares on December 31, 2025, to 603,016,125 shares, representing an increase of approximately 72.61%, reflecting strong confidence in the company.
- Key Fund Movements: Guardian Capital LLC exited its JNJ position in the latest 13F filings, indicating varying investment strategies and risk assessments within the market.
See More
Goldman Sachs Retirement Survey Reveals Optimism Gap
- Optimism Gap Phenomenon: The Goldman Sachs Retirement Survey reveals that while 68% of workers are confident about meeting retirement goals, 58% fear outliving their savings, highlighting a structural cost pressure that has reduced the capacity for retirement savings due to rising housing, childcare, and healthcare costs.
- Increased Spending Pressures: Since 2000, housing costs have risen from 21% to 36% of income, childcare from 10% to 25%, and healthcare from 12% to 33%, leading to 67% of respondents feeling overwhelmed by monthly expenses and 64% experiencing financial hardship, which directly impacts their retirement planning.
- Income Strategy Enhancement: The survey indicates that a blended income strategy combining protected lifetime income with investment withdrawals can increase retirement income by 23%, providing stability for essential expenses while addressing long-term growth needs, thereby alleviating financial pressure during retirement.
- Behavioral Factors Impact: Goldman’s research shows that retirees with personalized plans have a savings-to-income ratio of 5.92x compared to 4.68x for those without, underscoring the importance of combining structure and behavior in achieving better retirement outcomes and emphasizing the need for consistent saving and planning.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
